Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation

Netherlands Organisation for Applied Scientific Research (TNO)

Status: Completed

Conditions: Type 2 Diabetes; Cardiovascular Disease

Treatments: Behavioral: Alcohol: 25 gday (white wine)

Study type: Interventional

Funder types: Other

Identifiers

NCT00285909

Alcohol research 20

P6689

Details and patient eligibility

About

Moderate alcohol consumption is associated with a decreased risk of cardiovascular disease and type 2 diabetes. The association of alcohol consumption with cardiovascular disease is mediated by a functional polymorphism of alcohol dehydrogenase 1c, but the effect of this polymorphism on alcohol metabolism is only investigated in vitro.

The risk reduction of moderate alcohol consumption for cardiovascular disease is explained largely by an increase of HDL cholesterol, but an increase of adiponectin concentrations after moderate alcohol consumption may also be involved. It seems likely that adiponectin is a mediator for the association of moderate alcohol consumption with type 2 diabetes. The mechanism by which moderate alcohol consumption increases adiponectin concentrations is unknown, but ppar-gamma activation may be involved.

effects of this polymorphism on mediators of this relation are not known. This study therefore investigates the effect of moderate alcohol consumption and the influence of alcohol dehydrogenase 1c polymorphism on ppar-gamma activated gene expression and risk factors of cardiovascular disease and type 2 diabetes.

Full description

Objectives :

To investigate the effect of moderate alcohol consumption and influence of genetic variation of ethanol oxidation on:

• PPAR-γ activated gene expression
• Markers of coronary heart disease or type 2 diabetes
• Postprandial changes of HPA-axis activity among 36 postmenopausal women with ADH1C genotype associated with slow or fast alcohol metabolism.

Design : Randomized, controlled, not blinded crossover trial with 1 week wash-out preceding each treatment period

Participants

• Description : Apparently healthy postmenopausal women
• Number : 36

Study substances

• Test substance : White wine (ca. 25 g alcohol/day)
• Reference substance : White grape juice

Study treatments Treatment A: 250 ml white wine daily (ca. 25 g alcohol/day) Treatment B: 250 ml white grape juice daily

Study period

• Duration : two periods of 6 weeks preceded by 1 week wash-out period

Test parameters:

• Adiponectin mRNA expression
• Expression of PPAR-gamma activated genes: CD36, lipoprotein lipase, AP2
• Markers of cardiovascular disease (blood lipid profile, Lp-PLA2 activity, hs-CRP, fibrinogen)
• Markers of type 2 diabetes (adiponectin, adiponectin oligomers, insulin sensitivity)
• Parameters of alcohol oxidation (postprandial: blood alcohol and acetate, acetaldehyde)
• HPA-axis activity (postprandial & fasting: cortisol, ACTH, testosterone)

Sex: Female

Ages: 40 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy women aged 40 to 65 years
• Absence of menstrual period for at least 2 years
• Homozygotes for the ADH1C*1 or ADH1C*2 allele of ADH1C I349V polymorphism
• Alcohol consumption ≥ 5 and ≤ 21 units/week

Exclusion criteria

• Smoking
• Family history of alcoholism
• History of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disorders and gastrointestinal disorders
• Recent blood donation

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)